Global Regulators Agree On Acceptable Trial Endpoints For COVID-19 Treatments
Executive Summary
International regulators have agreed on primary endpoints that would be suitable for assessing the clinical benefit of an investigational therapeutic for COVID-19 and support regulatory approval.